The Role of Pharmacists in Community Oncology

October 16, 2024, at 12 p.m. EST

Join the Community Oncology Alliance Patient Advocacy Network (CPAN) for a virtual Advocacy Chat on Wednesday, October 16, at 12 p.m. ET to learn more about the importance of pharmacists to independent community oncology practices.

Previous Advocacy Chats

Each month, a special guest joins COA’s Director of Patient Advocacy & Education, Rose Gerber for a conversation on oncology and advocacy-related topics.

A prepared advocate is an effective advocate. That’s why COA and CPAN are working to provide advocates with the latest information on policy changes. As a new year begins, ensure you have the tools and knowledge you need to advocate for local, affordable cancer care.

View all past chats with full video playback, notes, and session slides.

Previous Advocacy Chats

Each month, a special guest joins COA’s Director of Patient Advocacy & Education, Rose Gerber for a conversation on oncology and advocacy-related topics.

A prepared advocate is an effective advocate. That’s why COA and CPAN are working to provide advocates with the latest information on policy changes. As a new year begins, ensure you have the tools and knowledge you need to advocate for local, affordable cancer care.

View all past chats with full video playback, notes, and session slides.

  • Between Life and Death: From Despair to Hope

    December 9, 2020 12:00 pm

    Kashyap Patel, MD

    On December 9, Kashyap Patel, MD, vice president of COA and CEO of Carolina Blood & Cancer Care Associates, joined COA Director of Patient Advocacy and Education Rose Gerber to discuss his new book, Between Life and Death: From Despair to Hope, a chronicle of real patients who have faced the end of life with understanding and acceptance. Dr. Patel described his experiences supporting patients with the transition to palliative care, offer strategies for dealing with this difficult issue, and more.

  • The 2020 State of Cancer Survivorship

    November 4, 2020 12:00 pm

    Shelley Fuld Nasso, MPP

    On November 4 at 12 p.m. ET, the COA Patient Advocacy Network (CPAN) hosted National Coalition for Cancer Survivorship(NCCS) CEO, Shelley Fuld Nasso, for an Advocacy Chat conversation with COA Director of Patient Advocacy and Education, Rose Gerber, about the 2020 State of Cancer Survivorship Survey and its implications for cancer care during a pandemic.

  • The Problem with White & Brown Bagging – What Patients Need to Know

    October 14, 2020 12:00 am

    Barbara L. McAneny, MD

    On October 14, 2020, Rose Gerber, Director of Patient Advocacy and Education at COA, was joined by guest Barbara L. McAneny, MD, a board-certified medical oncologist/hematologist from Albuquerque, N.M., immediate past president of the American Medical Association (AMA), and a long serving Community Oncology Alliance (COA) board member, for a discussion of the problems with white and brown bagging of cancer drugs.

  • Emotional and Financial Resources for Cancer Patients

    September 9, 2020 12:00 pm

    Patricia Goldsmith

    Cancer patients need compassion, care, and access to resources. The Community Oncology Alliance Patient Advocacy Network (CPAN) hosted a virtual Advocacy Chat on resources to address the emotional and financial needs of patients on Wednesday, September 9 from 12-12:30 p.m. ET. Our special guest was Patricia Goldsmith, CEO of CancerCare, a leading national organization providing free, professional support services and information to help people manage the emotional, practical, and financial challenges of cancer.

  • Where You’re Treated Makes a Difference

    August 12, 2020 12:00 pm

    Mark Thompson, MD

    There are many places where people with cancer can go for treatment, but not all cancer care is created equally. Community oncology is different because the doctors responsible for treating patients actually own and operate their local practices. Receiving cancer care at practices right in their own community is convenient for people with cancer – and their families – and typically costs less than treatment in a hospital setting, without sacrificing access to innovations like the latest procedures and clinical trials.